Communication of the meeting of Transparency Council No. 29/2025 in 14 July 2025 +resolutions
Transparency Council meeting protocol from meeting 14 July 2025 No. 29/2025:
- At its meeting on 14 July 2025, the Transparency Council adopted position No. 83/2025 on the appraisal of drug Bimzelx (bimekizumab) under drug program B.161 “Treatment of patients with suppurative apocrine sweat gland inflammation (HS) (ICD-10: L 73.2)”;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 119/2025 on the appropriateness of changing the reimbursement category of the active substance beksaroten and including it in the reimbursement scheme for a new indication;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 120/2025 on the appropriateness of changing the reimbursement category of the active substance denosumab and including it in the reimbursement scheme for new indications;
- At its meeting on 14 July 2025, the Transparency Council adopted position No. 84/2025 on the validity of granting authorizations for the reimbursement of medicinal products containing the active substance nadolol for the following indications: long QT syndrome, polymorphic ventricular tachycardia, hypertension, hypertrophic cardiomyopathy, Andersen-Tawila syndrome;
- At its meeting on 14 July 2025, the Transparency Council adopted position No. 85/2025 on the validity of granting authorizations for the reimbursement of the medicinal product Emcitate (tiratricol) for the indication: Allan-Herndon-Dudley syndrome;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 121/2025 on recommended medical technologies, measures implemented under health policy programs, and conditions for the implementation of these programs, concerning skin cancer prevention;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 122/2025 on recommended medical technologies, measures implemented under health policy programs, and conditions for the implementation of these programs, concerning the prevention of cerebrovascular diseases, in particular stroke;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 123/2025 on the draft program “Program of physiotherapy visits in the municipality of Trzebownisko in 2025-2029”;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 124/2025 on the inclusion of medicinal products containing the active substance cyclophosphamide in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. sarcoidosis; interstitial pneumonia – in cases other than those specified in the SPC – with the exception of idiopathic pulmonary fibrosis;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 125/2025 on the draft program “Health policy program for medical rehabilitation of seniors aged 60+ in the Municipality of Police for 2026”;
- At its meeting on 14 July 2025, the Transparency Council adopted opinion No. 126/2025 about the project “Comprehensive rehabilitation of children with disabilities from the town of Wodzisław Śląski”.